New and emerging treatments for metabolic dysfunction-associated steatohepatitis

Cell Metab. 2024 Apr 7:S1550-4131(24)00090-1. doi: 10.1016/j.cmet.2024.03.011. Online ahead of print.ABSTRACTMetabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic liver disease worldwide, with increasing incidence and prevalence in the setting of the obesity epidemic. MASH is also a leading indication for liver transplantation, given its associated risk of progression to end-stage liver disease. A key challenge in managing MASH is the lack of approved pharmacotherapy. In its absence, lifestyle interventions with a focus on healthy nutrition and regular physical activity have been the cornerstone of therapy. Real-world efficacy and sustainability of lifestyle interventions are low, however. Pharmacotherapy development for MASH is emerging with promising data from several agents with different mechanisms of action (MOAs) in phase 3 clinical trials. In this review, we highlight ongoing challenges and potential solutions in drug development for MASH and provide an overview of available data from emerging therapies across multiple MOAs.PMID:38608696 | DOI:10.1016/j.cmet.2024.03.011
Source: Cell Metabolism - Category: Cytology Authors: Source Type: research